OXNARD, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company researching cannabinoid molecules for various healthcare applications, today announces the appointment of Dr. Alan E. Einstein to its board of directors.
Dr. Alan Einstein, grandson to famed physicist Albert Einstein, has been practicing medicine since 1996. Currently working at EMC2Care in Alpharetta, Ga., he is considered a thought leader in metabolic syndrome and its role in weight gain and overall health and longevity. He has also conducted extensive research utilizing umbilical cord blood stem cells, with an interest in Parkinson’s disease and assisted Senator David Shafer in writing and passing Georgia’s only Cord Blood stem cell bill. Furthermore, in July 2006, Dr. Einstein was appointed to the, “Commission for Newborn Umbilical Cord Blood Research and Medical Treatment” by Georgia Governor Sonny Perdue.
“We here at CURE Pharmaceutical are always looking for innovators to be a part of our board of directors, to help us understand the needs in specific treatment areas,” said Rob Davidson, CEO of CURE Pharmaceutical. “Dr. Einstein’s addition to our board allows for increased depth in our medical expertise as we continue to work to expand our technical capabilities across all these specific areas. We look forward to utilizing his specific knowledge and experience as we continue to rapidly grow.”
Along with his work and knowledge in the areas of anti-aging and anti-inflammatory medicine, Dr. Einstein is a firm believer in the study of cannabis and cannabinoids for medicinal benefits. CURE is taking a leadership role in optimizing plant based cannabinoids with a strategy to bring new cannabinoid molecules to the market through the FDA regulatory approval process while utilizing the company’s proprietary delivery technologies.
“I am looking forward to being a part of CURE Pharmaceutical’s board of directors. Their drug delivery technologies are innovative technologies that I believe will benefit a growing number of people who require alternate ways to take medications, instead of the standard pill,” Dr. Einstein said. “Additionally, I am excited to see the upcoming research and partnerships that the company is planning in the medicinal cannabinoid area, as this is a growing market area that needs more research to help prove the benefits of these molecules.”
Dr. Einstein earned a bachelors of science degree in Physical Chemistry from The University of Florida. Subsequently, he earned his medical degree from The College of Osteopathic Medicine and Surgery in Des Moines, Iowa. Dr. Einstein then went on to complete his Internship and Residency training at The Johns Hopkins University School of Medicine/Sinai Hospital program in Internal Medicine, in Baltimore, MD.
About CURE Pharmaceutical
Cure Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs). Cure has an industry leading full service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. Cure has developed an array of products in cutting-edge delivery platforms. Cure is well positioned in the pharmaceutical cannabis sector and is developing a global footprint with partners in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to create solutions to improve the overall quality of life and deliver proven drugs in a fast and efficient manner.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Forward-looking statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.